Skip to Content

Generic Minastrin 24 Fe Availability

Minastrin 24 Fe is a brand name of ethinyl estradiol/norethindrone, approved by the FDA in the following formulation(s):

MINASTRIN 24 FE (ethinyl estradiol; norethindrone acetate - tablet, chewable;oral)

  • Manufacturer: APIL
    Approval date: May 8, 2013
    Strength(s): 0.02MG;1MG [RLD] [AB]

Has a generic version of Minastrin 24 Fe been approved?

A generic version of Minastrin 24 Fe has been approved by the FDA. However, this does not mean that the product will necessarily be commercially available - possibly because of drug patents and/or drug exclusivity. The following products are equivalent to Minastrin 24 Fe and have been approved by the FDA:

MIBELAS 24 FE (ethinyl estradiol; norethindrone acetate tablet, chewable;oral)

  • Manufacturer: LUPIN ATLANTIS
    Approval date: May 24, 2016
    Strength(s): 0.02MG;1MG [AB]

NORETHINDRONE ACETATE AND ETHINYL ESTRADIOL AND FERROUS FUMARATE (ethinyl estradiol; norethindrone acetate tablet, chewable;oral)

  • Manufacturer: AMNEAL PHARMS
    Approval date: September 11, 2017
    Strength(s): 0.02MG;1MG [AB]
  • Manufacturer: CHEMO RESEARCH SL
    Approval date: July 16, 2018
    Strength(s): 0.02MG;1MG [AB]
  • Manufacturer: GLENMARK PHARMS LTD
    Approval date: December 26, 2017
    Strength(s): 0.02MG;1MG [AB]
  • Manufacturer: MYLAN LABS LTD
    Approval date: September 12, 2017
    Strength(s): 0.02MG;1MG [AB]

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Minastrin 24 Fe. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: Generic Drug FAQs.

Related Patents

Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.

  • Chewable oral contraceptive
    Patent 6,667,050
    Issued: December 23, 2003
    Inventor(s): Roger M.; Boissonneault & Tina M.; deVries
    Assignee(s): Galen (Chemicals) Limited

    The present invention relates to a chewable, palatable oral contraceptive tablet, comprising an oral contraceptive agent, a chewable carrier suitable for human consumption, and not comprising a ferrocene compound, as well as use of these tablets in a method of human female oral contraception, and in a method of enhancing compliance with a human female oral contraceptive regimen.

    Patent expiration dates:

    • April 6, 2019
      Drug product

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Drug PatentA drug patent is assigned by the U.S. Patent and Trademark Office and assigns exclusive legal right to the patent holder to protect the proprietary chemical formulation. The patent assigns exclusive legal right to the inventor or patent holder, and may include entities such as the drug brand name, trademark, product dosage form, ingredient formulation, or manufacturing process A patent usually expires 20 years from the date of filing, but can be variable based on many factors, including development of new formulations of the original chemical, and patent infringement litigation.
Drug ExclusivityExclusivity is the sole marketing rights granted by the FDA to a manufacturer upon the approval of a drug and may run simultaneously with a patent. Exclusivity periods can run from 180 days to seven years depending upon the circumstance of the exclusivity grant.
RLDA Reference Listed Drug (RLD) is an approved drug product to which new generic versions are compared to show that they are bioequivalent. A drug company seeking approval to market a generic equivalent must refer to the Reference Listed Drug in its Abbreviated New Drug Application (ANDA). By designating a single reference listed drug as the standard to which all generic versions must be shown to be bioequivalent, FDA hopes to avoid possible significant variations among generic drugs and their brand name counterpart.
ABProducts meeting necessary bioequivalence requirements. Multisource drug products listed under the same heading (i.e., identical active ingredients(s), dosage form, and route(s) of administration) and having the same strength (see Therapeutic Equivalence-Related Terms, Pharmaceutical Equivalents) generally will be coded AB if a study is submitted demonstrating bioequivalence. In certain instances, a number is added to the end of the AB code to make a three character code (i.e., AB1, AB2, AB3, etc.). Three-character codes are assigned only in situations when more than one reference listed drug of the same strength has been designated under the same heading. Two or more reference listed drugs are generally selected only when there are at least two potential reference drug products which are not bioequivalent to each other. If a study is submitted that demonstrates bioequivalence to a specific listed drug product, the generic product will be given the same three-character code as the reference listed drug it was compared against.